 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...3839404142434445464748...208209» |
- AiRuiKa (camrelizumab) / HLB Bio Group
HIPEC combined with camrelizumab, paclitaxel and S-1 for conversion therapy in patients with advanced gastric cancer with peritoneal metastasis: A prospective phase II clinical study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5461;
Systemic chemoimmunotherapy and HIPEC combined with CRS is safe and feasible, and could potentially improve the prognosis of gastric cancer patients with limited peritoneal metastasis. However, further clinical trials are still warranted.
- AiTan (rivoceranib) / HLB Bio Group
A real-world study on epidemiology, biomarker test results, clinical characteristics, and treatment patterns of unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in China. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5454;
However, further clinical trials are still warranted. Oxaliplatin + tegafur was the most common 1L treatment, received by 3431/14,386 (23.8%) la/m Ga pts (median treatment duration: 2.9 mo [IQR: 1.4
- 5-fluorouracil / Generic mfg.
Sequential hepatic artery infusion chemotherapy and transarterial chemoembolization combined with anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors and immune checkpoint inhibitors (quadruple therapy) as first-line therapy for advanced hepatocellular carcinoma: A single-center retrospective cohort study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5445;
Sequential hepatic artery infusion chemotherapy and transarterial chemoembolization combined with anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors and immune checkpoint inhibitors achieved encouraging outcomes with accepted adverse events in advanced HCC patients. These findings warrant further validation in a large randomized clinical trial.
- Hetronifly (serplulimab) / Fosun Pharma
Continuation of serplulimab-based therapy beyond first progression in advanced gastric/gastroesophageal junction (G/GEJ) cancer: Preliminary results from the SCAFIGC trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5412;
P2
These findings warrant further validation in a large randomized clinical trial. All patients received 6-8 cycles of serplulimab combined with XELOX (oxaliplatin and capecitabine), followed by maintenance serplulimab plus capecitabine until disease progression, intolerable toxicity, or death...These patients were randomized (2:1) to receive serplulimab combined with apatinib and paclitaxel or paclitaxel
- AiRuiKa (camrelizumab) / HLB Bio Group
Efficacy of multimodal thermal therapy combined with immune checkpoint inhibitors and chemotherapy in unresectable pancreatic cancer with liver metastases. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5375;
P=N/A
All patients received 6-8 cycles of serplulimab combined with XELOX (oxaliplatin and capecitabine), followed by maintenance serplulimab plus capecitabine until disease progression, intolerable toxicity, or death...These patients were randomized (2:1) to receive serplulimab combined with apatinib and paclitaxel or paclitaxel Participants received MTT on at least one of the liver metastases combined with subsequent ICIs and chemotherapy (camrelizumab 200 mg IV on Day 1, gemcitabine 1000 mg/m
- Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / HLB Bio Group
A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5369;
P1
An RP2D of 125 mg dosage of palbociclib in combination was selected to be explored in further phase II study. Clinical trial information: NCT06654297.
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5356;
P2
Current results suggested the promising efficacy and acceptable safety of camrelizumab combined with CCRT in pts with locally recurrent esophageal cancer. The study enrollment is ongoing, and further survival and safety data will be reported in the future.
- AiRuiKa (camrelizumab) / HLB Bio Group
Assessing comparative efficacies of camrelizumab as a single or combination therapy in patients with hepatocellular carcinoma: A systematic review and network meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5320;
While TACE based regimens offered the highest immediate response and control rate, these therapies were associated with a significantly higher risk of chemotherapy-associated adverse events. Combination therapies with LEN or RIV significantly reduced the risk of adverse events, implying a safer profile.
- AiTan (rivoceranib) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5260;
However, apatinib may have a lower incidence of severe AEs. Further prospective studies with larger patient populations are required.
- AiRuiKa (camrelizumab) / HLB Bio Group, Aidixi (disitamab vedotin) / Pfizer
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5259;
P2
Further prospective studies with larger patient populations are required. The preliminary findings indicate that the neoadjuvant combination of RC48, camrelizumab and S-1 presents a promising and safe treatment option for locally advanced resectable GC/GEJ adenocarcinoma with HER2 overexpression.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5256;
Preoperative neoadjuvant therapy has reduced the rate of MVI. More data would be further analyzed and reported.
- AiTan (rivoceranib) / HLB Bio Group
STAR-01: A randomized phase III clinical trial comparing PD-1 combined with apatinib and SOX,PD-1 combined with SOX, versus SOX alone in patients with advanced gastric adenocarcinoma. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5254;
P4
In conversion therapy for advanced gastric cancer, the combination of PD-1+SOX could improve ORR, pCR, R0 resection rate and survival expectation of patients compared with SOX alone. However, whether apatinib is introduced or not can not improve the ORR rate and survival of patients.
- TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5230;
Previous study showed that nimotuzumab in combination with cisplatin and fluorouracil (PF) regimen reaching ORR of about 50%. The combination of camrelizumab and nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma can improve ORR and prolong OS of pts with controllable toxicity.
- Fruzaqla (fruquintinib) / Takeda
The appropriate therapeutic sequence with angiogenesis inhibitor and chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Exploratory analysis from the phase 3 FRUTIGA study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5229;
P3
This analysis revealed superior survival benefits in FP-C arm vs PP-AI arm, which indicates that compared with chemotherapy followed by angiogenesis inhibitor-based therapy, the therapeutic sequence of angiogenesis inhibitor-based therapy followed by chemotherapy may be predictive of better clinical outcomes for pts with advanced gastric or gastroesophageal junction adenocarcinoma. However, this exploratory analysis warrants further study.
- AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Perioperative camrelizumab plus apatinib and gemcitabine-oxaliplatin in patients with borderline resectable biliary tract malignancies: A multicenter, single-arm, phase II trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5225;
P2
Toxicities were manageable and consistent with the known safety profiles of these agents. These findings warrant further exploration of this regimen as a potentially effective multimodal treatment strategy.
- Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5224;
P2
Table 1. Survival outcomes.
- Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5223;
P=N/A
This regimen also demonstrates favorable outcomes in overall survival and significantly extends disease-free survival. These promising results support the continued investigation of this treatment approach.
- Epidaza (chidamide) / Chipscreen, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Efficacy of adebrelimab with chidamide, gemcitabine, and S-1 in locally advanced or metastatic pancreatic cancer: A phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5222;
P2
The ADEPT regimen showed promising antitumor activity and favorable tolerability as first-line therapy for locally advanced or metastatic pancreatic cancer. Further data from a large cohort and longer follow-up will be presented.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5220;
P2
Continued recruitment and follow-up are still ongoing. Clinical trail information: NCT06208462.
- Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Full-coverage therapy for converting unresectable advanced hepatocellular carcinoma. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5172;
Clinical trail information: NCT06208462. On Days 1
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Cryoablation combined with camrelizumab and apatinib in advanced hepatocellular carcinoma: A prospective, single-arm, phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5158;
P2
Cryoablation combined with apatinib and camrelizumab as the first-line strategy for aHCC patients with PVTT and below up-to-7 criteria demonstratebeld a promising value by improving ORR and OS with acceptable side effects. Baseline characteristics of patients
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Updated results of camrelizumab (Cam) plus low dose apatinib combined with gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract cancer (BTC): A single center, phase Ib/II trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5148;
P1/2
These results support low dose apatinib (250 mg, d1-d14, q3w) as an optimal dose combined with Cam and GP in aBTC. This combination strategy showed modest efficacy and tolerable toxicity in aBTC.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
A retrospective pilot study of neoadjuvant chemotherapy combined with immunotherapy in the treatment of thoracic esophageal squamous cell carcinoma with cervical lymph node metastasis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5133;
Further prospective trials are needed to fully evaluate the effectiveness and safety of this treatment strategy for these patients. Baseline Characteristics of the Patients
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5122;
P2
Adebrelimab combined with lenvatinib showed promising antitumor activity and manageable safety profile in patients with unresectable or metastatic ICC who had progressed on or were intolerant to first-line chemotherapy. These findings provide a rationale for further investigation of this regimen as a second-line treatment option.
- Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: A network meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5071;
Combination therapies with immune checkpoint inhibitors and chemotherapy improve survival in advanced or metastatic ESCC compared to chemotherapy alone. These findings support the use of novel immunotherapeutic agents to enhance patient outcomes, warranting further research to optimize treatment regimens and manage adverse events effectively.
- Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant therapy with mFOLFOXIRI combined with camrelizumab and bevacizumab for microsatellite stable, locally advanced rectal cancer: A single-arm, open-label phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5043;
P2
The ctDNA indicators can serve as biomarkers for predicting the efficacy and prognosis of neoadjuvant therapy. Postoperative Pathologic Findings
- Avastin (bevacizumab) / Roche, irinotecan hydrochloride liposome injection (HR070803) / Jiangsu Hengrui Pharma
The CREAFORMO-004 study: A phase II study of HR070803 plus 5-fluorouracil/leucovorin and bevacizumab as second-line treatment in patients with metastatic colorectal cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4926;
P=N/A
Irinotecan liposome (HR070803) in combination with 5-FU/LV and bevacizumab demonstrated promising efficacy and durability in this patient population. These results support further investigation of irinotecan liposome (HR070803) as a treatment option for patients with mCRC.
- VG161 / ViroGin Biotech
Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: A phase Ib/IIa clinical study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4700;
P1/2
Administration of VG161 3*10^8 PFU plus Camrelizumab 3 mg/kg per cycle is identified as RP2D. Further clinical studies are ongoing.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Efficacy and safety of dalpiciclib plus toremifene in advanced HR-positive HER2-negative breast cancer as first-line treatment: A multicenter, single-arm phase II trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4180;
P2
The combination of dalpiciclib and toremifene indicated a manageable, expected safety profile. This regimen may offer an viable first-line treatment option for HR+/HER2- mBC, especially for patients intolerant to aromatase inhibitors.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4178;
P=N/A
In real world, patients who received first-line pyrotinib-trastuzumab-based regimens achieved favorable effectiveness. With the continuous development of anti-HER2 therapy in the early stage, further exploration of pyrotinib-based regimens in the first-line treatment of HER2-positive advanced breast cancer is warranted.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: A multicenter real-world study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4171;
Patients with a longer initial PFS and extended TFI are likely to benefit more from re-treatment, warranting further evaluation. (ISRCTN Identifier: ISRCTN93654271).
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Epidaza (chidamide) / Chipscreen
Dalpiciclib plus chidamide in HR+/HER2- advanced breast cancer following CDK4/6 inhibitor treatment failure: Final results of a phase Ib trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4167;
P1
Our results revealed that dalpicilib plus chidamide achieved promising efficacy and safety in HR+/HER2- BC. The combination of dalpiciclib and chidamide may serve as an alternative treatment strategy in HR+/HER2- BC patients following CDK4/6i therapy failure.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: A multicenter real-world study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4157;
The updated analysis demonstrated that pyrotinib could be a good treatment option in HER2-positive MBC with acceptable toxicity in the real world. Survival is still under assessment with longer follow-up.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Correlation between the efficacy of anti-HER-2 targeted therapy and ctDNA status: A meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4083;
PIK3CA mutations predict worse outcomes in HER-targeted therapies, whereas ERBB2 mutations show inconsistent effects, likely influenced by other factors. In TKI-treated patients, ctDNA mutations, especially with pyrotinib, are robust predictors of reduced PFS, while their predictive value is limited in non-TKI therapies and non-capecitabine combinations.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase ? trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4057;
P2
Among these patients, 21 (70.0%) received abemaciclib, and 10 (33.3%) received palbociclib and ribociclib. Our results indicated that dalpiciclib plus fulvestrant and pyrotinib achieves promising efficacy and safety in in HR+, HER2-low advanced BC patients following CDK4/6i and AI treatment.
- pirotinib (KBP-5209) / Sihuan Pharmaceutical, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Multicenter real-world study of trastuzumab combined with pirotinib or pertuzumab as a neoadjuvant therapy for stage II-III HER-2 positive breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4025;
In the real-world study, HER-2 positive early breast cancer patients are more likely to use HP as neoadjuvant therapy, and HP are more likely to be used in combination with platinum drugs. Our study has confirmed that there is no significant difference in tpCR rates between HPy or HP.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Epidaza (chidamide) / Chipscreen
Dalpiciclib combined with chidamide and letrozole as neoadjuvant therapy for HR-positive, HER2-negative early or locally advanced breast cancer: A single-arm, prospective, exploratory clinical study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4022;
P4
Our results showed that the combination of dalpiciclib, chidamide and letrozole demonstrates an acceptable safety profile and promising clinical efficacy, suggesting its potential as an alternative fully oral, chemotherapy-free neoadjuvant treatment for HR-positive, HER2-negative early or locally advanced breast cancer. Further research is needed to validate these findings.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for triple negative breast cancer (TNBC): A single-arm, prospective phase II study (MA-BC-II-026). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_3921;
P2
In this single-center, prospective, non-randomized clinical trial, patients with newly diagnosed stage II-III TNBC in West China Hospital received a combination of camrelizumab (200 mg intravenouly every 2 weeks), apatinib (250 mg orally daily), and alternating chemotherapy (4 cycles of albumin paclitaxel and 4 cycles of epirubicin plus cyclophosphamide) for 8 cycles. Camrelizumab and apatinib combined with chemotherapy as neoadjuvant treatment for stage II-III TNBC has high clinical efficacy and favorable safety, which is worthy of further investigation and clinical application.
- SHR-A1912 / Jiangsu Hengrui Pharma
CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study. (E450a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3813;
P1/2
In pts with r/r DLBCL, SHR-A1912 at 1.8 mg/kg in combination with R-GemOx was tolerable and demonstrated a safety profile consistent with its individual components. This combination exhibited potent anti-tumor activity, as well as rapid and durable responses.
- Itari (linperlisib) / Shanghai YingLi Pharma
DLBCL-associated PIM1 mutation and its impact on ANXA2 localization and lymphomagenesis. (Hall A - Posters and Exhibits; Poster Bd #: 243) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3791;
This combination exhibited potent anti-tumor activity, as well as rapid and durable responses. Taken together, these findings not only shed light on an innovative regulatory mechanism for how PIM1L184F mutation contributes to the pathogenesis of DLBCL but also provide a potential therapeutic strategy for effectively managing DLBCL patients harboring PIM1L184F mutation.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial. (Hall D2) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3413;
P2
Our findings showed that SHR-A1811 6.4 mg/kg solely or SHR-A1811 4.8 mg/kg combined with bevacizumab both can attain high intracranial remission rates, while the lower-dose combination regimen might exhibit a better safety profile. The long-term outcomes will continue to be followed up.
- Avastin (bevacizumab) / Roche, Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Airuituo (bevacizumab biosimilar) / Jiangsu Hengrui Pharma
A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases. (Hall D2) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3410;
P2
Warranting further investigation in this highly aggressive disease. Clinical trial information: NCT04303988.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Eribulin plus pyrotinib In trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial). (Hall A - Posters and Exhibits; Poster Bd #: 10) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3405;
P4
The combination of eribulin and pyrotinib shows promise as a therapeutic option for patients with HER2-positive advanced breast cancer resistant to trastuzumab. While advancements in anti-HER2 therapies continue, further studies are needed to address unresolved challenges in this clinical context.
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus nab-paclitaxel and cisplatin as first-line treatment for metastatic triple-negative breast cancer: A prospective, single-arm, open-label phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 80) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3333;
P2
Camrelizumab plus AP as first-line treatment in patients with mTNBC demonstrated satisfying efficacy with manageable toxicity. Randomized controlled trial is warranted in the future.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
SHR-A1811 plus adebrelimab in unresectable or metastatic triple-negative breast cancer: Results from a phase 1b/2 expansion cohort. (Hall A - Posters and Exhibits; Poster Bd #: 82) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3320;
P2
The combination showed encouraging antitumor activity in unresectable or metastatic TNBC, irrespective of HER2 or PD-L1 expression status. Phase 2 preliminary efficacy summary.11HER2 and PD-L1 results were based on central lab assessment.
- famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: 32-month follow-up from a single-center exploratory study. (Hall A - Posters and Exhibits; Poster Bd #: 336) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3257;
P=N/A
Famitinib demonstrated sustained clinical efficacy and meaningful survival benefits in pts with FAP-associated aggressive DTs after a median follow-up of 32 months. Given the unique characteristics, careful monitoring for intestinal perforation and the risk of second primary tumors is crucial during treatment.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. (E451) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3060;
P2
Stage 1 results of CAP 03-NEO demonstrated the potential of neoadjuvant camrelizumab, apatinib and temozolomide in pts with resectable stage II/III AM. The pNR result support advancing to stage 2 to further assess the efficacy and safety of this regimen in pts with stage III disease.
- AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Safety and effectiveness of fuzuloparib in patients with ovarian cancer: A nationwide, multicenter, prospective real-world study. (Hall A - Posters and Exhibits; Poster Bd #: 470) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2756;
P=N/A
In the real-world setting, fuzuloparib shows favorable safety, with no new safety signals. The effectiveness outcomes align with trends observed in key clinical trials.
- Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead
IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers (Hall A - Posters and Exhibits; Poster Bd #: 525a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2700;
P2
Translational research projects will be developed to unravel the cellular and molecular mechanisms involved in treatment response. Moreover, data from the prospectively implemented database of the French Gestational Trophoblastic Disease Center will be analyzed to create a synthetic historical arm representative of the efficacy of the standard treatments in a similar patient population.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811 in patients (pts) with HER2-expressing advanced gynecological cancers (Gynecol C): A phase 2 study. (Hall A - Posters and Exhibits; Poster Bd #: 510) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2698;
P2
aIn pts with baseline and at least one post-baseline assessments; N was 41, 26, 33, 100, 37, 25, 31, and 93. bIn pts with confirmed CR or PR; N was 23, 13, 21, 57, 21, 13, 19, and 53.